enGene Therapeutics ENGN

Health care sectorNasdaq

Company

Exchange: Nasdaq
Sector: Health care
Industry: Biological Products, (No Diagnostic Substances)
Headquarters: Saint-Laurent
Fiscal year end: 10/31
Next earnings: 12/08, estimated

No member of Congress reported a trade in enGene Therapeutics ENGN in the past 90 days. Insiders filed 1 purchase and 0 sales on the open market over the same period, a net purchase of $10.1K.

Korean holdings rank: Outside the top 50; Korea Securities Depository · released 09/22
Congress trades: No record; Last 90 days · 0 buys · 0 sales
Insider net buying: +$10.1K; Last 90 days · bought $10.1K · sold $0
Next earnings: 12/08; Estimated from the last four quarters

26-week trading

Common questions

Did enGene Therapeutics ENGN insiders buy or sell in the past 90 days?: In the past 90 days insiders filed 1 purchase and 0 sales on the open market. Purchases came to $10.1K.